Cargando…

Donor UNC-93 Homolog B1 genetic polymorphism predicts survival outcomes after unrelated bone marrow transplantation

UNC-93 homolog B1 (UNC93B1) is a key regulator of toll-like receptors (TLRs), pattern recognition receptors that sense invading pathogens and manage the innate immune response and deliver them from the endoplasmic reticulum to their respective endosomal signaling compartments. Several types of TLRs...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchino, Kaori, Vu Quang, Lam, Mizuno, Shohei, Horio, Tomohiro, Yamamoto, Hidesuke, Hanamura, Ichiro, Kodera, Yoshihisa, Luis Espinoza, J., Onizuka, Makoto, Kashiwase, Koichi, Morishima, Yasuo, Fukuda, Takahiro, Doki, Noriko, Miyamura, Koichi, Mori, Takehiko, Morishita, Eriko, Nakao, Shinji, Takami, Akiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903020/
https://www.ncbi.nlm.nih.gov/pubmed/33627833
http://dx.doi.org/10.1038/s41435-021-00122-y
Descripción
Sumario:UNC-93 homolog B1 (UNC93B1) is a key regulator of toll-like receptors (TLRs), pattern recognition receptors that sense invading pathogens and manage the innate immune response and deliver them from the endoplasmic reticulum to their respective endosomal signaling compartments. Several types of TLRs are known to contribute to the inflammatory process after allogeneic hematopoietic stem cell transplantation (SCT), so UNC93B1 might play integral roles there. We investigated the influence of the UNC93B1 single-nucleotide polymorphism (SNP) rs308328 (T>C) on transplant outcomes in a cohort of 237 patients undergoing unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program. The donor UNC93B1 C/C genotype was associated with a better 3-year overall survival than the donor UNC93B1 C/T or T/T genotype. An analysis of the UNC93B1 rs308328 genotype may therefore be useful for selecting the donor, estimating the prognosis, and creating therapeutic strategies after allogeneic SCT.